Ascendis Pharma A/S
ASND
36 hedge funds and large institutions have $146M invested in Ascendis Pharma A/S in 2015 Q1 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
14.92% more ownership
Funds ownership: 0% → 14.92% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$26.3M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
+$18.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.8M |
| 4 |
VHCP Management
New York
|
+$14.8M |
| 5 |
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$13.3M |
Top Sellers
ASND Hedge Fund Activity: Q1 2015 in Review
36 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2015, worth a combined $146M.
Buyers outnumbered sellers: 36 funds opened new ASND positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $26.3M.
- 36 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $146M of Ascendis Pharma A/S stock for Q1 2015.
- 36 funds opened new Ascendis Pharma A/S positions in Q1 2015 and 0 closed out, a net change of +36 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2015 was OrbiMed, an estimated $26.3M added.
Based on aggregated 13F filings for Q1 2015.